pdufa date for tirzepatide FDA Calendar, PDUFA Dates, FDA Approval Dates Vepdegestrant: The First Phase 3–Positive

usually most pronounced during dose escalation Diarrhea : Affects 12-17% of patients, typically mild to moderate in severity Vomiting : Reported in 6-10% of patients, more common at higher doses Constipation : Occurs in 6-11% of patients Abdominal pain and dyspepsia : Generally transient Decreased appetite : An expected pharmacological effect contributing to weight loss Other documented adverse effects include injection site reactions, hypoglycemia (when used with insulin or sulfonylureas), and less commonly, fatigue

Understanding potential side effects puts you in a stronger position to manage them and keep moving forward with confidence

What you need before starting One 10mg retatrutide vial (lyophilized powder) One vial of bacteriostatic water (BAC water) One sterile syringe with needle (3mL syringe works well for mixing) Alcohol swabs Clean, flat work surface A quick note on water type

Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis

Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, Acampora R, Passariello N, Cacciapuoti F, Paolisso G